Oncology drug health technology assessment recommendations: Canadian versus UK experiences
I Chabot, A Rocchi - ClinicoEconomics and Outcomes Research, 2014 - Taylor & Francis
Background Canada has two health technology assessment (HTA) agencies responsible for
oncology drug funding recommendations: the Institut National d'Excellence en Santé et …
oncology drug funding recommendations: the Institut National d'Excellence en Santé et …
Common Drug Review recommendations: an evidence base for expectations?
A Rocchi, E Miller, RB Hopkins, R Goeree - Pharmacoeconomics, 2012 - Springer
Abstract Background: The Common Drug Review (CDR) was created to provide a single
process to review the comparative clinical efficacy and cost effectiveness of new drugs, and …
process to review the comparative clinical efficacy and cost effectiveness of new drugs, and …
Therapies for advanced cancerspose a special challenge for health technology assessment organizations in many countries
PJ Neumann, SK Bliss, JD Chambers - Health Affairs, 2012 - healthaffairs.org
Health technology assessment organizations evaluate medical therapies and technologies
to help inform coverage and reimbursement decisions for payers around the globe. Even as …
to help inform coverage and reimbursement decisions for payers around the globe. Even as …
Availability of medicines
H Jenzer, S Groesser, N Miljković - … Guideline for the Preparation, Care and …, 2023 - Springer
Fundamental changes and new challenges have been emerging in the last decades as a
result of the globalisation of markets and of production, new economic doctrines, tight …
result of the globalisation of markets and of production, new economic doctrines, tight …
[PDF][PDF] 3. Market Access in the UK
FB Yenilmez - 2018 - pdfs.semanticscholar.org
The UK healthcare system is primarily governed by the National Health Service (NHS), a
body that commissions services such as general practitioners (GPs), pharmacists and …
body that commissions services such as general practitioners (GPs), pharmacists and …